Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis, Medquest Ink Distribution Deal for Singapore, Malaysia

NEW YORK – IsoPlexis said on Tuesday that it has signed an exclusive agreement with Medquest to distribute IsoPlexis' products in Singapore and Malaysia.

Financial terms of the agreement were not disclosed.

Based in Branford, Connecticut, IsoPlexis markets products for single-cell proteomics research, including the IsoLight System, an automated platform for comprehensive functional protein and metabolite profiling of single cells.

"Our IsoLight platform provides a wide range of applications across numerous disease areas and we are excited for our systems to generate impactful data at leading pharmaceutical and life science institutions in Singapore and Malaysia," IsoPlexis CEO Sean Mackay said in a statement.

In July, IsoPlexis announced an exclusive distribution agreement in China with Neoline Technology.

Last week, IsoPlexis said that Switzerland-based Lonza will use the IsoLight platform for functional quality analytics for cell therapy products produced on Lonza's automated cell manufacturing platform. Also in August, IsoPlexis said it is partnering with researchers at Columbia University to study immune response in COVID-19 patients.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more